Major Established

설명

Concurrent use of cyclosporine and tacrolimus dramatically amplifies nephrotoxicity and is generally contraindicated; both agents independently cause renal vasoconstriction and tubular injury.

기전

Both calcineurin inhibitors reduce renal afferent arteriolar blood flow through increased thromboxane A2 and endothelin-1 production and decreased prostacyclin; the combination produces additive/synergistic renal vasoconstriction. Additionally, cyclosporine inhibits CYP3A4 and P-gp, raising tacrolimus levels.

임상적 중요성

Transplant registries report significantly higher rates of acute kidney injury and chronic allograft nephropathy when both CNIs are co-administered, even briefly.

관리 방법

Concurrent use is contraindicated in most transplant protocols; if transitioning from cyclosporine to tacrolimus, allow a 24-hour washout before starting tacrolimus and monitor renal function closely.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.